男性乳腺癌的研究进展  

Research Progress of Male Breast Cancer

作　　者：邓锋[1] 阿迪力江.买买提明 栾梅香[1] 地力木拉提.艾斯木吐拉 

机构地区：[1]新疆医科大学第一附属医院乳腺外科,新疆乌鲁木齐830054

出　　处：《中国普外基础与临床杂志》2016年第12期1538-1543,共6页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的总结男性乳腺癌(male breast cancer,MBC)的病因、治疗等方面的研究进展。方法通过阅读文献的方法,对MBC的病因、治疗等进行综述。结果家族史、乳腺癌易感蛋白1/2(BRCA1/2)基因突变、雌雄激素水平不平衡等众多因素是导致MBC发生的危险因素。前哨淋巴结活检(sentinel lymph node biopsy,SLNB)在MBC患者中具有可行性。放疗可以控制MBC的局部复发,化疗可能对远期生存率有益。MBC的内分泌治疗原则不能完全等同于女性乳腺癌(female breast cancer,FBC)。结论 MBC的危险因素众多,放化疗及内分泌治疗均可使MBC患者获益,但仍需大样本、高质量的临床研究论证。Objective To summarize the research progress of the cause, treatment, and other aspects in male breast cancer （MBC）. Methods Through reading the related literatures, relevant literatures of MBC were reviewed. Results Family history, BRCA1/2 mutation, the imbalance of level of estrogen and androgen, and other factors were risk factors of the MBC. Sentinel lymph node biopsy （SLNB） was feasible in the MBC. Radiotherapy could control local recurrence of MBC, and chemotherapy may be beneficial for long-term survival rate of MBC. The endocrine therapy principle for MBC was not exact as female breast cancer （FBC）. Condusions MBC has many risk factors. Radiotherapy, chemotherapy, and endocrine therapy are benefit to MBC patients, but it still needs to be confirmed by many high-quality clinical researches of large sample.

关 键 词：男性乳腺癌 危险因素 治疗 

分 类 号：R737.9[医药卫生—肿瘤]